Cargando…

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?

BACKGROUND: The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological information for their occurrence. The aim was to investigate the relationship bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloniecki, Victor, Zetterberg, Henrik, Aarsland, Dag, Vannini, Patrizia, Kvartsberg, Hlin, Winblad, Bengt, Blennow, Kaj, Freund-Levi, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670701/
https://www.ncbi.nlm.nih.gov/pubmed/33203439
http://dx.doi.org/10.1186/s13195-020-00718-y
_version_ 1783610790870253568
author Bloniecki, Victor
Zetterberg, Henrik
Aarsland, Dag
Vannini, Patrizia
Kvartsberg, Hlin
Winblad, Bengt
Blennow, Kaj
Freund-Levi, Yvonne
author_facet Bloniecki, Victor
Zetterberg, Henrik
Aarsland, Dag
Vannini, Patrizia
Kvartsberg, Hlin
Winblad, Bengt
Blennow, Kaj
Freund-Levi, Yvonne
author_sort Bloniecki, Victor
collection PubMed
description BACKGROUND: The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological information for their occurrence. The aim was to investigate the relationship between NPS and CSF biomarkers for synaptic (neurogranin [Ng], growth-associated protein 43 [GAP-43]) and axonal (neurofilament light [NFL]) injury in patients with dementia. METHODS: A total of 151 patients (mean age ± SD, 73.5 ± 11.0, females n = 92 [61%]) were included, of which 64 had Alzheimer’s disease (AD) (34 with high NPS, i.e., Neuropsychiatric Inventory (NPI) score > 10 and 30 with low levels of NPS) and 18 were diagnosed with vascular dementia (VaD), 27 with mixed dementia (MIX), 12 with mild cognitive impairment (MCI), and 30 with subjective cognitive impairment (SCI). NPS were primarily assessed using the NPI. CSF samples were analyzed using enzyme-linked immunosorbent assays (ELISAs) for T-tau, P-tau, Aβ1–42, Ng, NFL, and GAP-43. RESULTS: No significant differences were seen in the CSF levels of Ng, GAP-43, and NFL between AD patients with high vs low levels of NPS (but almost significantly decreased for Ng in AD patients < 70 years with high NPS, p = 0.06). No significant associations between NPS and CSF biomarkers were seen in AD patients. In VaD (n = 17), negative correlations were found between GAP-43, Ng, NFL, and NPS. CONCLUSION: Our results could suggest that low levels of Ng may be associated with higher severity of NPS early in the AD continuum (age < 70). Furthermore, our data may indicate a potential relationship between the presence of NPS and synaptic as well as axonal degeneration in the setting of VaD pathology.
format Online
Article
Text
id pubmed-7670701
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76707012020-11-18 Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration? Bloniecki, Victor Zetterberg, Henrik Aarsland, Dag Vannini, Patrizia Kvartsberg, Hlin Winblad, Bengt Blennow, Kaj Freund-Levi, Yvonne Alzheimers Res Ther Research BACKGROUND: The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological information for their occurrence. The aim was to investigate the relationship between NPS and CSF biomarkers for synaptic (neurogranin [Ng], growth-associated protein 43 [GAP-43]) and axonal (neurofilament light [NFL]) injury in patients with dementia. METHODS: A total of 151 patients (mean age ± SD, 73.5 ± 11.0, females n = 92 [61%]) were included, of which 64 had Alzheimer’s disease (AD) (34 with high NPS, i.e., Neuropsychiatric Inventory (NPI) score > 10 and 30 with low levels of NPS) and 18 were diagnosed with vascular dementia (VaD), 27 with mixed dementia (MIX), 12 with mild cognitive impairment (MCI), and 30 with subjective cognitive impairment (SCI). NPS were primarily assessed using the NPI. CSF samples were analyzed using enzyme-linked immunosorbent assays (ELISAs) for T-tau, P-tau, Aβ1–42, Ng, NFL, and GAP-43. RESULTS: No significant differences were seen in the CSF levels of Ng, GAP-43, and NFL between AD patients with high vs low levels of NPS (but almost significantly decreased for Ng in AD patients < 70 years with high NPS, p = 0.06). No significant associations between NPS and CSF biomarkers were seen in AD patients. In VaD (n = 17), negative correlations were found between GAP-43, Ng, NFL, and NPS. CONCLUSION: Our results could suggest that low levels of Ng may be associated with higher severity of NPS early in the AD continuum (age < 70). Furthermore, our data may indicate a potential relationship between the presence of NPS and synaptic as well as axonal degeneration in the setting of VaD pathology. BioMed Central 2020-11-17 /pmc/articles/PMC7670701/ /pubmed/33203439 http://dx.doi.org/10.1186/s13195-020-00718-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bloniecki, Victor
Zetterberg, Henrik
Aarsland, Dag
Vannini, Patrizia
Kvartsberg, Hlin
Winblad, Bengt
Blennow, Kaj
Freund-Levi, Yvonne
Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title_full Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title_fullStr Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title_full_unstemmed Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title_short Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
title_sort are neuropsychiatric symptoms in dementia linked to csf biomarkers of synaptic and axonal degeneration?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670701/
https://www.ncbi.nlm.nih.gov/pubmed/33203439
http://dx.doi.org/10.1186/s13195-020-00718-y
work_keys_str_mv AT blonieckivictor areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT zetterberghenrik areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT aarslanddag areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT vanninipatrizia areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT kvartsberghlin areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT winbladbengt areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT blennowkaj areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration
AT freundleviyvonne areneuropsychiatricsymptomsindementialinkedtocsfbiomarkersofsynapticandaxonaldegeneration